Search

Your search keyword '"Naru, Jasmine"' showing total 26 results
Start Over Author "Naru, Jasmine"
26 results on '"Naru, Jasmine"'

1. Verification of prognostic expression biomarkers is improved by examining enriched leukemic blasts rather than mononuclear cells from acute myeloid leukemia patients

Author

Pogosova-Agadjanyan, Era L., Hua, Xing, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., Erba, Harry P., Fitzgibbon, Matthew P., Jenkins, Isaac C., Fang, Min, Lee, Stanley C., Moseley, Anna, Naru, Jasmine, Radich, Jerald P., Smith, Jenny L., Willborg, Brooke E., Willman, Cheryl L., Wu, Feinan, Meshinchi, Soheil, and Stirewalt, Derek L.

Published
2023
Full Text
View/download PDF

3. AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Author

Pogosova-Agadjanyan, Era L., Moseley, Anna, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., Chen, I-Ming L., Erba, Harry P., Godwin, John E., Jenkins, Isaac C., Fang, Min, Huynh, Mike, Kopecky, Kenneth J., List, Alan F., Naru, Jasmine, Radich, Jerald P., Stevens, Emily, Willborg, Brooke E., Willman, Cheryl L., Wood, Brent L., Zhang, Qing, Meshinchi, Soheil, and Stirewalt, Derek L.

Published
2020
Full Text
View/download PDF

5. Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research Network

Author

Termini, Christina M., primary, Moseley, Anna, additional, Othus, Megan, additional, Appelbaum, Frederick R., additional, Chauncey, Thomas R., additional, Erba, Harry P., additional, Fang, Min, additional, Lee, Stanley C., additional, Naru, Jasmine, additional, Pogosova-Agadjanyan, Era L., additional, Radich, Jerald P., additional, Willman, Cheryl L., additional, Wu, Feinan, additional, Meshinchi, Soheil, additional, and Stirewalt, Derek L., additional

Published
2023
Full Text
View/download PDF

6. Profiling of urinary proteins in Karan Fries cows reveals more than 1550 proteins

Author

Bathla, Shveta, Rawat, Preeti, Baithalu, Rubina, Yadav, Munna Lal, Naru, Jasmine, Tiwari, Anurag, Kumar, Sudarshan, Balhara, Ashok K., Singh, Surender, Chaudhary, Suman, Kumar, Rajesh, Lotfan, Masoud, Behare, Pradip, Phulia, Sushil K., Mohanty, Tushar K., Kaushik, Jai K., Nallapeta, Shivramaiah, Singh, Inderjeet, Ambatipudi, Srinivas K., and Mohanty, Ashok K.

Published
2015
Full Text
View/download PDF

8. Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report

Author

Naru, Jasmine, primary, Othus, Megan, additional, Lin, ChenWei, additional, Moseley, Anna, additional, Willman, Cheryl L, additional, Pogosova-Agadjanyan, Era L, additional, Wu, Feinan, additional, Appelbaum, Frederick R., additional, Erba, Harry P., additional, Jenkins, Isaac C., additional, Kennedy, Jacob J, additional, Delrow, Jeffrey, additional, Whiteaker, Jeffrey, additional, Radich, Jerald P., additional, Godwin, John E., additional, Beppu, Lan, additional, Fitzgibbon, Matthew, additional, Fang, Min, additional, Wang, Pei, additional, Gafken, Phillip R, additional, Ivey, Richard G, additional, Meshinchi, Soheil, additional, Chauncey, Thomas R., additional, Lorentzen, Travis D, additional, Voytovich, Uliana J, additional, Paulovich, Amanda G, additional, and Stirewalt, Derek, additional

Published
2021
Full Text
View/download PDF

9. Global Proteomic Profiling Identifies Novel Prognostic Factors in Undifferentiated Leukemia Blasts from Patients with NPM1 Mutations: A Previously Unreported Approach to Biomarker Discovery from the Fred Hutch and SWOG

Author

Stirewalt, Derek, primary, Othus, Megan, additional, Naru, Jasmine, additional, Kennedy, Jacob J, additional, Pogosova-Agadjanyan, Era L, additional, Appelbaum, Frederick R., additional, Beppu, Lan, additional, Chauncey, Thomas R., additional, Delrow, Jeffrey, additional, Erba, Harry P., additional, Gafken, Phillip R, additional, Godwin, John E., additional, Fitzgibbon, Matthew, additional, Hua, Xing, additional, Jenkins, Isaac C., additional, Fang, Min, additional, Ivey, Richard G, additional, Lin, ChenWei, additional, Lorentzen, Travis D, additional, Moseley, Anna, additional, Radich, Jerald P., additional, Voytovich, Uliana J, additional, Wang, Pei, additional, Whiteaker, Jeffrey, additional, Willman, Cheryl L, additional, Wu, Feinan, additional, Meshinchi, Soheil, additional, and Paulovich, Amanda G, additional

Published
2021
Full Text
View/download PDF

11. 3009 – MIS-SPLICING OF TMEM14C ALTERS PORPHYRIN AVAILABILITY PROMOTING RING SIDEROBLAST FORMATION IN SF3B1-MUTANT MYELODYSPLASTIC SYNDROMES

Author

Clough, Courtnee, primary, Pangallo, Joseph, additional, Sarchi, Martina, additional, Ilagan, Janine, additional, North, Khrystyna, additional, Bergantinos, Rochelle, additional, Naru, Jasmine, additional, Nugent, Patrick, additional, Kim, Eunhee, additional, Stirewalt, Derek, additional, Subramaniam, Arvind, additional, Abdel-Wahab, Omar, additional, Abkowitz, Janis, additional, Bradley, Robert, additional, and Doulatov, Sergei, additional

Published
2021
Full Text
View/download PDF

12. Additional file 1 of AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report

Author

Pogosova-Agadjanyan, Era L., Moseley, Anna, Othus, Megan, Appelbaum, Frederick R., Chauncey, Thomas R., I-Ming L. Chen, Erba, Harry P., Godwin, John E., Jenkins, Isaac C., Fang, Min, Huynh, Mike, Kopecky, Kenneth J., List, Alan F., Naru, Jasmine, Radich, Jerald P., Stevens, Emily, Willborg, Brooke E., Willman, Cheryl L., Wood, Brent L., Zhang, Qing, Meshinchi, Soheil, and Stirewalt, Derek L.

Abstract

Additional file 1: Table S1. Targeted Sequencing Details. Table S1A. Target regions for Wafergen Sequencing. Table S1B Primers and Amplicon Details for Wafergen Sequencing. Table S1C. Primers for CEBPA targeted MiSeq Assay. Table S2. Loci that Failed Quality Control. Table S3. Characteristics of selected and unselected SWOG patients. Fig. S1. Comparison of Performance Characteristics of selected and unselected SWOG patients. Table S4. Characteristics of SWOG patients in the discovery and validation cohorts. Fig. S2. Comparison of Performance Characteristics of SWOG patients in the discovery and validation cohorts. Table S5. Mutation distribution in discovery and validation cohorts. Fig. S3. Mutation Frequency (OncoPrint). Table S6. Expression fold change differences between MNCs and VLBs in discovery cohort. Table S7. Univariate analyses results, non-significant findings Models Details. Table S8. ELN2017 versus ELN2017-MOD risk assignment in MNCs and VLBs.

Published
2020
Full Text
View/download PDF

13. AML Risk Stratification Models Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Author

Pogosova-Agadjanyan, Era L, primary, Moseley, Anna, additional, Othus, Megan, additional, Appelbaum, Frederick R., additional, Chauncey, Thomas R., additional, Chen, I-Ming L., additional, Erba, Harry P., additional, Godwin, John E., additional, Jenkins, Isaac C., additional, Fang, Min, additional, Huynh, Mike, additional, Kopecky, Kenneth J., additional, List, Alan F., additional, Naru, Jasmine, additional, Radich, Jerald P., additional, Stevens, Emily, additional, Willborg, Brooke E., additional, Willman, Cheryl L., additional, Wood, Brent L., additional, Zhang, Qing, additional, Meshinchi, Soheil, additional, and Stirewalt, Derek L., additional

Published
2020
Full Text
View/download PDF

14. Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Author

Pogosova-Agadjanyan, Era L, primary, Moseley, Anna, additional, Othus, Megan, additional, Appelbaum, Frederick R., additional, Chauncey, Thomas R., additional, Chen, I-Ming L., additional, Erba, Harry P., additional, Godwin, John E., additional, Jenkins, Isaac C., additional, Fang, Min, additional, Huynh, Mike, additional, Kopecky, Kenneth J, additional, List, Alan F., additional, Naru, Jasmine, additional, Radich, Jerald P., additional, Stevens, Emily, additional, Willborg, Brooke E, additional, Willman, Cheryl L., additional, Wood, Brent L, additional, Zhang, Qing, additional, Meshinchi, Soheil, additional, and Stirewalt, Derek, additional

Published
2019
Full Text
View/download PDF

15. Identification of a Novel AML Patient Subset Sensitive to Venetoclax Using Matched Proteomics and Diverse Ex Vivo Models

Author

Jackson, Pilgrim, Stirewalt, Derek, Sorrentino, James, Martinez de Bartolome Izquierdo, Salvador, Abbasian, Mahan, Bates, Robert, and Naru, Jasmine

Abstract

AML is one of the most common and deadly hematopoietic malignancies. The molecular and biological heterogeneity of AML poses significant challenges to the identification of novel agents to treat it and the optimal triage of patients for the most effective therapeutic regimens. Ex vivomodels for drug sensitivity using cell lines and/or primary AML samples have been a fruitful resource for the exploration and discovery of novel compounds in the treatment of AML, and investigators have coupled genomic and transcriptomic profiling with ex vivomodels in the hope to further enhance the reliability and accuracy of results. However, primary AML blasts are molecularly complex and fastidious, relying on extracellular matrix (ECM) and signals for optimal survival, making their use for large, high-throughput drug screens impractical. Available AML cell lines are more robust and less dependent upon the ECM but often harbor strong driver alterations (e.g., KMT2Arearrangements, TP53mutations) that occur in only a small subpopulation of AML cases. Thus, current AML cell lines may not accurately predict agent sensitivity for most patients. Here, we report the results of a novel approach coupling cutting-edge proteomics with ex vivodrug sensitivity models to develop and describe a more diverse and representative set of patient-derived cell models for drug discovery and therapeutic positioning. Initial studies focused on proteomic biomarker signatures and cell lines to predict drug sensitivity for Venetoclax, which has become a stable component for treatment of older and unfit patients with AML.

Published
2023
Full Text
View/download PDF

18. Identification of potential protein biomarkers for early detection of pregnancy in cow urine using 2D DIGE and label free quantitation

Author

Rawat, Preeti, primary, Bathla, Shveta, additional, Baithalu, Rubina, additional, Yadav, Munna Lal, additional, Kumar, Sudarshan, additional, Ali, Syed Azamal, additional, Tiwari, Anurag, additional, Lotfan, Masoud, additional, Naru, Jasmine, additional, Jena, Manoj, additional, Behere, Pradip, additional, Balhara, Ashok K., additional, Vashisth, Rajesh, additional, Singh, Inderjeet, additional, Dang, Ajay, additional, Kaushik, Jai K., additional, Mohanty, Tushar K., additional, and Mohanty, Ashok K., additional

Published
2016
Full Text
View/download PDF

21. Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel

Author

Sehrawat, Urmila, primary, Pokhriyal, Ruchika, additional, Gupta, Ashish Kumar, additional, Hariprasad, Roopa, additional, Khan, Mohd Imran, additional, Gupta, Divya, additional, Naru, Jasmine, additional, Singh, Sundararajan Baskar, additional, Mohanty, Ashok Kumar, additional, Vanamail, Perumal, additional, Kumar, Lalit, additional, Kumar, Sunesh, additional, and Hariprasad, Gururao, additional

Published
2016
Full Text
View/download PDF

26. Coordinated mis-splicing of TMEM14C and ABCB7 causes ring sideroblast formation in SF3B1-mutant myelodysplastic syndrome

Author

Clough, Courtnee A., Pangallo, Joseph, Sarchi, Martina, Ilagan, Janine O., North, Khrystyna, Bergantinos, Rochelle, Stolla, Massiel C., Naru, Jasmine, Nugent, Patrick, Kim, Eunhee, Stirewalt, Derek L., Subramaniam, Arvind R., Abdel-Wahab, Omar, Abkowitz, Janis L., Bradley, Robert K., and Doulatov, Sergei

Abstract

SF3B1splicing factor mutations are near-universally found in myelodysplastic syndromes (MDS) with ring sideroblasts, a clonal hematopoietic disorder characterized by abnormal erythroid cells with iron-loaded mitochondria. Despite this remarkably strong genotype-to-phenotype correlation, the mechanism by which mutant SF3B1 dysregulates iron metabolism to cause ring sideroblasts (RS) remains unclear due to an absence of physiological models of RS formation. Here, we report an induced pluripotent stem cell (iPSC) model of SF3B1-mutant MDS that for the first time recapitulates robust RS formation during in vitroerythroid differentiation. Mutant SF3B1 induces mis-splicing of ~100 genes throughout erythroid differentiation, including proposed RS driver genes TMEM14C, PPOX,and ABCB7. All three mis-splicing events reduce protein expression, notably occurring via 5’ UTR alteration and reduced translation efficiency for TMEM14C. Functional rescue of TMEM14C and ABCB7, but not the non-rate-limiting enzyme PPOX, markedly decreased RS, and their combined rescue nearly abolished RS formation. Our study demonstrates that coordinated mis-splicing of mitochondrial transporters TMEM14Cand ABCB7by mutant SF3B1 sequesters iron in mitochondria, causing ring sideroblast formation.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results